(Q67897237)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1824653%20AND%20SRC:MED&resulttype=core&format=json

18 September 2019

title

Double-blind comparison of doxazosin and enalapril in patients with mild or moderate essential hypertension (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1824653%20AND%20SRC:MED&resulttype=core&format=json

Cardiology and cardiovascular medicine

18 September 2019

main subject

essential hypertension

1 reference

1 reference

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

3 December 2022

author name string

F. Wessels

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1824653

3 December 2022

language of work or name

English

0 references

publication date

1 January 1991

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1824653%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

18 September 2019

https://api.elsevier.com/content/article/PII:000287039190862C?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

https://api.elsevier.com/content/article/PII:000287039190862C?httpAccept=text/plain

3 December 2022

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

3 December 2022

published in

American Heart Journal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1824653%20AND%20SRC:MED&resulttype=core&format=json

18 September 2019

volume

121

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1824653%20AND%20SRC:MED&resulttype=core&format=json

18 September 2019

page(s)

299-303

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1824653%20AND%20SRC:MED&resulttype=core&format=json

18 September 2019

issue

1 Pt 2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1824653%20AND%20SRC:MED&resulttype=core&format=json

Acute and chronic haemodynamic effects of doxazosin in hypertension at rest and during exercise

18 September 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

Clinical pharmacological studies with doxazosin

3 December 2022

2

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

A pharmacodynamic and pharmacokinetic assessment of a new alpha- adrenoceptor antagonist, doxazosin (UK33274) in normotensive subjects

3 December 2022

3

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

Within patient comparison of prazosin and UK-33,274. A new alpha-adrenoceptor-antagonist

3 December 2022

4

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

Doxazosin in patients with hypertension

3 December 2022

5

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

A long-term double-blind comparison of doxazosin and atenolol in patients with mild to moderate essential hypertension

3 December 2022

6

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

Multicentre 12-week double-blind comparison of doxazosin, prazosin and placebo in patients with mild to moderate essential hypertension

3 December 2022

7

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure

3 December 2022

9

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

Stratifying the patient at risk from coronary disease: new insights from the Framingham Heart Study.

3 December 2022

10

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

Changing perspectives in the prevention of coronary artery disease

3 December 2022

15

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

Double-blind comparison of the effects of long-term treatment with doxazosin or atenolol on serum lipoproteins

3 December 2022

16

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

The antihypertensive effects of doxazosin: a clinical overview

3 December 2022

17

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

Serum lipid changes in a one-year, multicenter, double-blind comparison of doxazosin and atenolol for mild to moderate essential hypertension

3 December 2022

18

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

Multicenter, double-blind comparison of doxazosin and atenolol in patients with mild to moderate hypertension

3 December 2022

19

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

Effect of doxazosin monotherapy on blood pressure and plasma lipids in patients with essential hypertension

3 December 2022

20

1 reference

https://api.crossref.org/works/10.1016/0002-8703(91)90862-C

3 December 2022

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1824653%20AND%20SRC:MED&resulttype=core&format=json

18 September 2019

1 reference